Home › Free Stock Grades › SGP
SpyGlass Pharma, Inc. Common Stock (SGP) Stock Grade
SGP · Healthcare
A+
Market Cap
$882.5M
P/E Ratio
—
Revenue Growth (YoY)
0.0%
Net Margin
0.0%
Return on Equity
40.3%
Dividend Yield
None
About SpyGlass Pharma, Inc. Common Stock's fundamentals
SpyGlass Pharma is a $882.5M biotech company currently reporting no revenue growth and zero net margin, indicating the company is not yet profitable and generated a net loss in its latest annual statement. Despite the lack of current profitability, the company's return on equity stands at 40.3%, suggesting efficient use of shareholder capital on an accounting basis. The company does not pay a dividend, which is typical for early-stage biotech firms that reinvest capital into research and development operations.